GlaxoSmithKline Plc: Is The Dividend Safe?

Here I explain my own view on the implications of GlaxoSmithKline Plc’s (LON: GSK) investor day, along with my assessment of the dividend outlook

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There has been no respite for Glaxo (LSE: GSK) shares in recent weeks as investors have remained unenthused by the company’s performance, with the stock falling by 6% during the month and bringing shareholders a year-to-date loss of 5.1% on their holdings.  

Much of this recent performance has been due to the fact that the much vaunted R&D day at the beginning of this month left investors somewhat underwhelmed.

Management spoke a lot about how they could file for regulatory approval on up to 20 new drugs before 2020. However, 20% of the total appear to be generics, while the board only sees seven of twenty as having a chance of actually coming onto market before 2020.

This obviously prompts a number of questions, so for those who are wondering whether it is worth holding onto the shares, here are some more thoughts.

Far from secure

The disappointment in R&D now places a significant question mark over Glaxo’s ability to maintain its dividend commitments through till 2020.

Based on current forecasts, at least some of the dividend will need to be paid from reserves in the current year, as the consensus for 2015 suggests earnings per share will be in the region of 77.0p. In plain English, this means dividend cover of sub 1x.

The outlook for 2016 doesn’t appear much better either, with current estimates suggesting earnings per share of 85.1p, which is also below the likely level of total dividends for the period.

Furthermore, if we assume that Glaxo’s future income stability is far from secured by its current pipeline, we are forced to accept that M&A may become a necessity for management.

This will probably mean the issuance of debt as well as the drawing down of reserves, which only serves to make the dividend outlook all the more questionable.

The wild card

The wild card in all of this appears to be GSK’s HIV business, which has performed better than many expected in recent periods.

If forecasters are to be believed then the ViiV Healthcare franchise could bring in up to £2.5bn annually for Glaxo by the close of 2017, which is a significant shot in the arm in terms of revenue.

However, this still leaves the group staring down the barrel of a significant revenue gap if it’s Advair business falls all of the way into obscurity during the same time period and, as such, it is not possible to say whether a successful performance in HIV will be enough for Glaxo.

Preserve of the patient

Despite the above, it is not all doom and gloom.

The investment case for the group remains strong over the long term, with the option of outward M&A still a viable strategy over the near-medium term, while ongoing scope for a more robust approach to costs could still help to smooth over some of the creases in the coming years.

Furthermore, recent chatter from across the pond has highlighted the potential for inbound M&A to also be a source of shareholder returns, with Pfizer executives ‘fessing up’ to having contacted GSK about the prospect of a tie up.

At present GSK trades at 16.9x the consensus estimate for earnings per share in 2015, which represents a modest premium to comparable peers such as Astrazeneca and Shire but a discount to the 17.4x sector average.

My guess is that the group will either continue to pursue organic growth over the medium term or management will finally put their heads together and come up with a credible M&A strategy.

Regardless of which option they eventually go for, it’s looking increasingly like it is only a matter of time before investors begin to question the viability of GSK’s commitment to a progressive dividend.

This could prove a further headwind for the shares over the near to medium term, which means that new or continued investment into Glaxo will probably remain the preserve of the patient for at least the foreseeable future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Skinner has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

£20,000 tucked away? Here’s how I’d aim for a £29,664-a-year passive income

This Fool wants to debunk the myth that making passive income is impossible. With £20,000, here's how he'd do it.

Read more »

Dividend Shares

Starting with £0, here’s how I’d turn my Stocks and Shares ISA into a second income machine

Jon Smith explains how compounding his dividend payments can help him to grow his Stocks and Shares ISA from a…

Read more »

Happy parents playing with little kids riding in box
Investing Articles

A 9.7%-yielding FTSE 100 dividend gem that could create generational wealth

A sizeable investment pot that can be passed onto the next generation could be built with much smaller investments over…

Read more »

Investing Articles

Up 31%, do Lloyds shares have more to give?

Shares in major FTSE 100 bank Lloyds are on a charge. But what could be in store for the stock?…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Time to sell this FTSE 100 underperformer, says Goldman Sachs

Analysts at one investment bank have a ‘sell’ rating on FTSE 100 stock Diageo. But could a short-term weakness in…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Down 5%, Glencore’s share price looks a serious bargain to me now

Glencore’s share price looks undervalued to me, supported by strong earnings growth prospects and the potential resumption of extra shareholder…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

I’d invest £6,580 in this FTSE 250 REIT for £500 passive income

This FTSE 250 renewable energy enterprise is on track to become a Dividend Aristocrat! Here’s how I’d invest to earn…

Read more »

Investing Articles

Buying 1,000 of some dividend shares today unlocks £45 in weekly passive income!

These shares are among the biggest dividend payers in the FTSE 100. Should investors be buying them now to earn…

Read more »